2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 978

Light Mediated Therapeutics in Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1527

Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1225

Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1659

Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1288

Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice

Muscle Biology, Myositis & Myopathies Poster II

9:00AM-11:00AM: Abstract Number: 989

Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1032

Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1667

Long Term Outcome of Hydralazine-Associated Vasculitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1491

Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1542

Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1417

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1543

Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1692

Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1733

Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1534

Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].